Platshon Scott 4

What Happened
Platshon Scott, EVP and Chief Business Officer of Zymeworks Inc. (ZYME), received three equity awards (derivative grants) on April 9, 2026 totaling 193,000 units: 70,000; 47,000; and 76,000. Each grant is reported at $0.00 per unit (standard for compensatory awards). These are awards/grants (transaction code A) rather than purchases or open-market sales — i.e., compensation tied to service and/or performance, not a cash buy or sale.

Key Details

• Transaction date: 2026-04-09; filing date: 2026-04-10 (appears timely).
• Counts and price: 70,000; 47,000; and 76,000 units; $0.00 per unit; total units = 193,000.
• Nature: Reported as derivative awards (could include stock options, restricted stock units (RSUs) and/or performance RSUs (PSUs)); no cash paid.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Notable footnotes in the filing:
  • F1: Stock options (if any) vest 25% after one year, then monthly over 36 months.
  • F2–F3: RSUs (if any) convert 1-for-1 to common shares on vesting; RSUs vest in four equal annual installments starting on the first anniversary.
  • F4–F5: PSUs (if any) are performance-based tied to cumulative total shareholder return (TSR) over a three-year period (performance period ends Jan 12, 2029); target PSUs shown as 38,000 with payout range 50%–200% of target depending on TSR; vesting generally conditioned on continued service with limited exceptions (e.g., certain terminations or change in control).

Context: These awards are compensation intended to align management incentives with shareholder performance and typically vest over time or upon meeting performance targets. They are not the same as an insider buying shares (which some investors view as a bullish signal) or selling shares (which may be routine). For PSUs, final share delivery depends on future performance certification at the end of the performance period.